Covalon Announces Participation In Ontario Government’s Medical Trade Mission To Mexico

MISSISSAUGA, Ontario – June 7, 2016 – /Business Wire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be one of six companies participating in this year’s Ontario Trade Medical Mission to Mexico. As part of the trade mission, Covalon will be a featured company at the Ontario Government’s pavilion at EXPOMED Exhibition and Congress from June 8 to 10 in Mexico City.

“Mexico is key to accelerating our business in Latin America” said John R. Hands, Covalon’s Executive Vice President. “By leveraging the infrastructure and connections that the Ontario Ministry of Citizenship, Immigration and International Trade has established, we have secured key meetings with key medical opinion leaders, healthcare practitioners and potential distribution partners. Consistent with our model in other geographic markets, this trade mission allows us to efficiently increase our brand awareness and establish key relationships within the region.”

EXPOMED Mexico 2016 is the most important international health and innovation forum in Mexico, with the most complete, state-of-the-art technologies and products for both private and public health institutions that benefit the development activities of the sector. Expected participants include local key opinion leaders, healthcare practitioners, medical society members, as well as members of the business, and educational communities.

In addition to the pavilion at EXPOMED, the Ontario Government’s mission is planning several events including on-site visits and presentations to high-quality private hospitals as well as business to business meetings at the Ontario pavilion during the exposition.

Visit Covalon at the Ontario Pavilion at EXPOMED Exhibition and Conference at the World Trade Center, Mexico City, June 8-10, 2016.

To learn more about Covalon, please contact:

Brian Pedlar, CEO, Covalon Technologies Ltd.

Email: bpedlar@covalon.com

Phone: 905.568.8400 x 233

Toll free: 1.877.711.6055

Web site: www.covalon.com

Twitter: @covalon

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results

and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

---

https://ir.covalon.com/press-releases?item=194